New York, NY – According to filings with the U.S. Securities and Exchange Commission, Oculogica is raising $8,571,753.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Rosina Samadani played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Oculogica

Founded by a neurosurgeon and research scientist, Oculogica has developed the first FDA authorized non-invasive, baseline free, technology to aid in diagnosis of concussion, also known as mild traumatic brain injury (mTBI). Oculogica is also conducting research with world-class medical institutions to bring personalized medicine to concussion diagnosis and treatment, and, ultimately, improve outcomes for the millions of people who annually suffer TBI and concussion..

To learn more about Oculogica, visit http://www.oculogica.com/

Contact:
Rosina Samadani, Chief Executive Officer
484-393-2694
https://www.linkedin.com/in/rsamadani/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved